Medium-chain fat supplementation in children with biliary atresia: a retrospective review

Retrospective medical records review to investigate the association between medium-chain triglyceride supplementation with growth, nutritional status and clinical outcomes in children with biliary atresia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN85147447

Enrollment

200

Registered

2023-06-01

Start date

2023-04-01

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric gastroenterology, hepatology and nutrition Digestive System

Interventions

Design and aim The study will examine the medical records of 200 children with biliary atresia that were previously looked after in the Trust, many of whom received different amounts of medium-chain f

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Biliary atresia diagnosis 2. Kasai portoenterostomy procedure performed at King’s College Hospital 3. Followed up at King's College Hospital for two years or until liver transplant or death if this occurred before two years

Exclusion criteria

Exclusion criteria: Serious comorbidities/ diseases (e.g. cardiac illness, chromosomal abnormalities, congenital malformations)

Design outcomes

Primary

Measure	Time frame
The following outcomes including medium-chain triglyceride (MCT) supplementation, growth and nutritional status and clinical outcomes are measured using patient medical records: MCT supplementation MCT intake (g/kg/day) prescription (% MCT) and duration of supplementation (months) determined based on caregiver-reported nutritional intake obtained at baseline, 6 weeks, 3 months, 6 months, 12 months and 24 months post kasai portoenterostomy Growth and nutritional status 1. Growth measurements (weight, length, head circumference, mid-upper arms circumference) obtained at baseline, 6 weeks, 3 months, 6 months, 12 months and 24 months post kasai portoenterostomy and converted to age- and sex-adjusted z-scores. 2. Fat-soluble vitamin status (serum concentrations of vitamin A, vitamin D and vitamin E) at baseline, 6 weeks, 3 months, 6 months, 12 months and 24 months post kasai portoenterostomy Clinical outcomes 1. Two-year outcome is classed as good (survival with native liver) or poor (transplant/listed for transplant/death) at two years post kasai portoenterostomy 2. Post-transplant outcome for those who are transplanted is determined at six months post-transplant and is classed as good (survival) or poor (re-transplant/listed for re-transplant/death) 3. Morbidity at the time of the analysis 4. Paediatric End-Stage Liver Disease score measured at baseline, 6 weeks, 3 months, 6 months, 12 months and 24 months post kasai portoenterostomy 5. The presence of ascites confirmed on abdominal ultrasound at baseline, 6 weeks, 3 months, 6 months, 12 months and 24 months post kasai portoenterostomy 6. Number of episodes of gastrointestinal bleeding and cholangitis recorded in the two years following kasai portoenterostomy 7. Liver function (serum albumin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, total bilirubin, gamma-glutamyl transferase and INR) obtained at baseline, 6 weeks, 3 months, 6 months, 12 months and 24 months post kasai portoenter	—

Measure

Time frame

The following outcomes including medium-chain triglyceride (MCT) supplementation, growth and nutritional status and clinical outcomes are measured using patient medical records: MCT supplementation MCT intake (g/kg/day) prescription (% MCT) and duration of supplementation (months) determined based on caregiver-reported nutritional intake obtained at baseline, 6 weeks, 3 months, 6 months, 12 months and 24 months post kasai portoenterostomy Growth and nutritional status 1. Growth measurements (weight, length, head circumference, mid-upper arms circumference) obtained at baseline, 6 weeks, 3 months, 6 months, 12 months and 24 months post kasai portoenterostomy and converted to age- and sex-adjusted z-scores. 2. Fat-soluble vitamin status (serum concentrations of vitamin A, vitamin D and vitamin E) at baseline, 6 weeks, 3 months, 6 months, 12 months and 24 months post kasai portoenterostomy Clinical outcomes 1. Two-year outcome is classed as good (survival with native liver) or poor (transplant/listed for transplant/death) at two years post kasai portoenterostomy 2. Post-transplant outcome for those who are transplanted is determined at six months post-transplant and is classed as good (survival) or poor (re-transplant/listed for re-transplant/death) 3. Morbidity at the time of the analysis 4. Paediatric End-Stage Liver Disease score measured at baseline, 6 weeks, 3 months, 6 months, 12 months and 24 months post kasai portoenterostomy 5. The presence of ascites confirmed on abdominal ultrasound at baseline, 6 weeks, 3 months, 6 months, 12 months and 24 months post kasai portoenterostomy 6. Number of episodes of gastrointestinal bleeding and cholangitis recorded in the two years following kasai portoenterostomy 7. Liver function (serum albumin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, total bilirubin, gamma-glutamyl transferase and INR) obtained at baseline, 6 weeks, 3 months, 6 months, 12 months and 24 months post kasai portoenter

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

England, United Kingdom

Contacts

Public ContactSara Mancell

sara.mancell@nhs.net+44 (0)203 299 4434

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026